



# GENERALI AKCJE BIOPHARMA

Equity sub-fund



Generali Akcje Biopharma allows to benefit from the potential of global biotechnology, pharmaceutical and healthcare companies. Historical data show that they were more profitable than traditional market companies and their advantage may further increase. The sub-fund performs in an innovational master feeder formula: Generali Akcje Biopharma invests its assets in participation units of the UniSector: Biopharma fund, managed by Union Investment, which has delivered excellent performance since 1999.

## Sub-fund performance



Recommended minimal investment horizon:




## Sub-fund performance\*

	1 month	3 months	6 months	1 year	2 years	5 years	10 years
<b>Generali Akcje Biopharma (%)</b>	2.31	13.03	16.57	26.82	28.11	-	-

\* Performance of the sub-fund is calculated on the basis of last working days of each month. Data based on own calculations from December 30, 2019.

On January 11, 2020, the investment policy and the name of the fund will change. New fund name - Generali Akcji Europejskich.

## Geographical allocation of equity portfolio



## Currency structure



**Marek Straszak**  
Sub-fund Manager

## Sub-fund profile

Master Fund	UniSector: BioPharma A
Master Fund type	Equity sub-fund
Date of first fund pricing	1 October 2015
Maximum front-load fee according to table of fees	5%
Minimal initial payment	1,000 PLN
Minimal next payments	1,000 PLN
Maximum management fee	3.5%
Actual management fee	2.95%
Sub-fund Manager	Marek Straszak
Net asset value	9.25 mln PLN
Value of participation unit	134,53 PLN
Bank account numbers	97 1880 0009 0000 0013 0105 5000

## Investor profile

The sub-fund is addressed to investors, who:

- want to benefit from holding participation units of UniSector: Biopharma which invests mainly in companies from the pharmaceutical, healthcare and biotechnology sector,
- have a long-term investment horizon (at least 7 years),
- understand the sub-fund's very high investment risk.

## 10 biggest positions

JOHNSON & JOHNSON	6.40%
MERCK & CO.	5.50%
VERTEX PHARMACEUTICALS INC.	4.96%
THERMO FISHER SCIENTIFIC	4.17%
ROCHE HLD. GS	4.08%
PFIZER	4.01%
HYMN	3.84%
HUMANA	3.70%
UNITEDHEALTH GROUP	3.70%
STRYKER CORPORATION	3.15%

## Risk measures (for 12 months)

Beta to WIG	0.33
Sharpe's ratio	2.80
Standard deviation	9.01%

## Dictionary

**Beta to WIG** – this ratio shows the relation between changes in the value of a fund unit and changes in the WIG index. Beta of 1 means that changes in the value of a fund unit are the same as changes in the WIG index. Beta below 1 means that a growth (decrease) in the benchmark by 1% is usually connected with a growth (decrease) in the value of the WIG index by less than 1%. Beta over 1 means that a growth (decrease) in the WIG index by 1% is usually connected with a growth (decrease) in the value of a fund unit by more than 1%.

**Sharpe's ratio** – this ratio shows the profitability of risk borne by the fund compared to safe investments (e.g. treasury bonds). The higher the Sharpe's ratio, the lower the risk at which the return of the fund is generated compared to safe investments.

**Standard deviation** – this ratio shows how risky the given fund is. The higher the ratio, the more volatile the price of a fund unit. This ratio is used to compare the risk of funds with a similar profile (e.g. equity funds).

This material is distributed to advertise or promote services provided by Generali Investments TFI S.A.

Presented financial information concerns the indicated period in the past and does not constitute a guarantee of achievement of similar results in the future. The result presented does not include front-load fees associated with investing in a given sub-fund or taxes. Front-load fees and applicable taxes may be deducted from the result.

The Generali Euro sub-fund is denominated in EUR. Incoming and outgoing payments by way of purchase or sale of participation units in the sub-fund are made in EUR. In the event a participant intends to obtain investment returns in a currency other than EUR, the participant must take into account the fact that any returns may increase or decrease as a result of currency fluctuations.

The Generali Dolar sub-fund is denominated in USD. Incoming and outgoing payments by way of purchase or sale of participation units in the sub-fund are made in USD. In the event a participant intends to obtain investment returns in a currency other than USD, the participant must take into account the fact that any returns may increase or decrease as a result of currency fluctuations.

No guarantee of achievement of the objectives of the investment funds; there is a possibility of a decrease in value, including the loss of a part of the invested funds.

**A high volatility of the net asset value: Generali Akcje Małych i Średnich Spółek, Generali Akcje Wzrostu, Generali Akcje: Nowa Europa, Generali Korona Akcje, Generali Korona Zrównoważony, Generali Stabilny Wzrost, Generali Obligacje: Nowa Europa, Generali Akcje: Turcja, Generali Globalnych Akcji Wzrostu in Generali Fundusze<sup>FIO</sup> and Generali Obligacje Aktywne, Generali Obligacje Globalne Rynki Wschodzące, Generali Akcje: Daleki Wschód, Generali Euro, Generali Akcje Biopharma, Generali Akcje Selektowny Globalny, Generali Zagraniczny in Generali Fundusze<sup>FIO</sup>.**

The possibility of the deposit more than 35% of assets of Generali Korona Dochodowy, Generali Korona Obligacje, Generali Stabilny Wzrost, Generali Korona Zrównoważony, Generali Akcje: Daleki Wschód, Generali Aktywne Dochodowy, Generali Zagraniczny, SGB Dłużny, Generali Aktywa Polskie in securities issued or guaranteed by the Polish Treasury or the Polish National Bank, and in the case of Generali Dolar, Generali Obligacje: Nowa Europa, Generali Akcje: Turcja, Generali Globalnych Akcji Wzrostu and Generali Oszczędnościowy also in securities issued or guaranteed by: Australia, Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Malta, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Turkey, United States of America and the European Investment Bank and World Bank (The International Bank for Reconstruction and Development).

Information prospectuses, Key investor information, information for clients of AIF, tables of fees, information on investment risk and taxes are available through the website: [www.generali-investments.pl](http://www.generali-investments.pl).

Generali Investments TFI S.A. operates under a licence from the Securities and Exchange Commission (currently: Polish Financial Supervision Authority) of 1 June 1995, no. of decision KPW-4073-1\95.

## Any questions?



801 144 144  
(+48) 22 449 03 33 (Monday to Friday from 8:00 to 18:00)



[tfi@generali-investments.pl](mailto:tfi@generali-investments.pl)

